B&K Co., Ltd, a biopharmaceutical company specializing in protein drug development and headquartered in Qingdao, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company’s IPO details, including pricing, have not yet been disclosed. Since its establishment in 2012, B&K has focused on research and development (R&D) of multifunctional therapeutics for wound healing, with platelet-derived growth factor (PDGF) drugs at the forefront. Its core products, Pro-101-1 and Pro-101-2, which are recombinant human PDGF-BB (rhPDGF-BB) drugs, are currently undergoing Phase II and Phase IIb clinical trials for the treatment of burns and diabetic foot ulcers, respectively.
In 2022 and 2023, B&K reported financial losses of RMB 85.93 million and RMB 105 million, accompanied by R&D expenses of RMB 34.8 million and RMB 39.9 million for the respective years. As of December 31, 2023, the company’s cash and cash equivalents stood at RMB 241.5 million.- Flcube.com
